[ ![Lock Image](/themes/custom/cosmos/icons/lock-image.png) ](/arctic_media_access_logs_modal_form?media-hcp=12801) 

 

Description

The JULIET clinical trial is a global, multi-center Phase II registration trial investigating CTL019 (tisagenlecleucel) for use in diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL). The Novartis-sponsored JULIET trial was conducted in collaboration with the University of Pennsylvania to evaluate the safety and efficacy of CTL019 in adult patients with relapsed or refractory (r/r) DLBCL. Relapsed/refractory DLBCL is an aggressive (fast-growing), complex and difficult-to-treat disease, and patients with DLBCL often have worse prognosis than other forms of NHL.



 

 

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.



 

 [ ![Lock Image](/themes/custom/cosmos/icons/lock-image.png) ](/arctic_media_access_logs_modal_form?media-hcp=12801) 

 [   Download (PDF 132.99 KB)  ](/arctic_media_access_logs_modal_form?media-hcp=12801)